Trial Profile
Phase II multicentric study to evaluate the efficacy and the safety of Bendamustine in adjunct to Etoposide, Aracytabin and Melphalan (BeEAM) as a preparative regimen for autologous stem cell transplantation in refractory/relapsed lymphoma patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 03 Dec 2012
Price :
$35
*
At a glance
- Drugs Bendamustine (Primary) ; Cytarabine; Etoposide; Melphalan
- Indications Chronic lymphocytic leukaemia; Hodgkin's disease; Lymphoma; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Acronyms BeEAM
- 01 Aug 2011 New trial record